WO2016154277A1 - Kits and methods of using enzymes to modify polysaccharide fillers and delivery systems - Google Patents

Kits and methods of using enzymes to modify polysaccharide fillers and delivery systems Download PDF

Info

Publication number
WO2016154277A1
WO2016154277A1 PCT/US2016/023726 US2016023726W WO2016154277A1 WO 2016154277 A1 WO2016154277 A1 WO 2016154277A1 US 2016023726 W US2016023726 W US 2016023726W WO 2016154277 A1 WO2016154277 A1 WO 2016154277A1
Authority
WO
WIPO (PCT)
Prior art keywords
polysaccharide
mass
enzyme
agalsidase
kit
Prior art date
Application number
PCT/US2016/023726
Other languages
French (fr)
Inventor
Leonard B. MILLER
Original Assignee
Advanced Aesthetic Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Aesthetic Technologies, Inc. filed Critical Advanced Aesthetic Technologies, Inc.
Priority to EP16769585.7A priority Critical patent/EP3344064A4/en
Publication of WO2016154277A1 publication Critical patent/WO2016154277A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0036—Galactans; Derivatives thereof
    • C08B37/0039—Agar; Agarose, i.e. D-galactose, 3,6-anhydro-D-galactose, methylated, sulfated, e.g. from the red algae Gelidium and Gracilaria; Agaropectin; Derivatives thereof, e.g. Sepharose, i.e. crosslinked agarose

Definitions

  • Embodiments of the present invention were not conceived or reduced to practice with Federal sponsorship.
  • Polysaccharides are used as cosmetic fillers and as a component of injectable drug delivery systems.
  • the polysaccharides may have a long period of time before such are resorbed into the body through metabolism or other means.
  • Embodiments of the present invention facilitate the use of polysaccharides, particularly as such polysaccharides are used as fillers and drug delivery vehicles.
  • Embodiments of the present invention allow the polysaccharide to be modified in vivo or in vitro to impart special physical and chemical properties. For example, without limitation, the physical properties of texture, feel, resistance to pressure, viscosity and the like can be altered or modified, in vivo or in vitro. Similarly, the chemical properties resistance to degradation and speed of degradation can be modified or altered.
  • polysaccharide fillers used for cosmetic purposes typically comprise solutions of 1.0 to 5.0 %. These solutions may also comprise other materials to improve the flow or feel of the filler, such as hyaluronic acid, and anesthetic agents to address the potential discomfort during the administration of the filler. Anesthetic agents are well known in the art and include, without limitation, lidocaine. These fillers are administered to the deep layer of the skin.
  • One embodiment of the present invention is directed to a method of altering or modifying a mass comprising a polysaccharide held in the body of an animal.
  • the method comprises the steps of administering an effective amount of an enzyme for the polysaccharide to the mass.
  • the enzyme can be administered to the mass prior to the mass being placed in the body or after the mass has been placed in the body.
  • One embodiment of the method features a polysaccharide having one or more sugars selected from the group consisting of D-galactose and 3, 6-anhydro-L-galactopyranose.
  • a "drug delivery vehicle” comprises a polysaccharide and one or more drugs.
  • One embodiment of the method features an enzyme, alpha-galactosidase.
  • the enzyme is known in recombinant forms asagalsidase, in alpha and beta forms.
  • the enzyme is selected from the group consisting of agalsidase alpha and agalsidase beta.
  • Algalsidase beta is sold under the mark FABRAZYME ® (Genzyme, Cambridge, MA 02142).
  • Algalsidase alpha is sold in Europe under the mark REPLAGAL ® (Shire, Dublin, Ireland).
  • the enzyme has utility to remove the polysaccharide, control the delivery or release of drug and minimize the mark on the skin from the injection of drug.
  • one embodiment of an invention directed to a drug delivery system comprises a polysaccharide and an enzyme for said polysaccharide held in a vessel for reconstitution. Upon reconstitution, the enzyme begin metabolizing the polysaccharide. This metabolizing may continue after injection of the drug delivery system into a patient.
  • drug is used to refer to any compound or compounds used to effect a biological change or treat a medical condition. The drug may be incorporated into the polysaccharide prior to reconstitution or after
  • a further embodiment of the present invention is directed to a kit for performing dermal filling procedures or for the administration of drug.
  • the kit comprises a polysaccharide for forming a mass in the body of an animal and an enzyme for degrading the polysaccharide for administration to the mass held in the body to effect a modification or speeding the resorption of said mass.
  • One embodiment of the present kit features a polysaccharide having one or more sugars selected from the group consisting of D-galactose and 3, 6-anhydro-L-galactopyranose. These sugars are constituents of the polysaccharide, agarose.
  • agalsidase is selected from the group consisting of agalsidase alpha and agalsidase beta.
  • Figure 1 depicts a kit embodying features of the present invention. Detailed Description of the Invention
  • kits for performing dermal filling procedures or for the administration of drug will now be described in detail with respect to a kit for performing dermal filling procedures or for the administration of drug.
  • the present description is directed to embodiments which are considered to be the best mode to practice the present invention at the time of the writing of the present description. Those skilled in the art will recognize that the understanding of the best mode may change in time. Those skilled in the art will also recognize that the features of the present invention described are subject to alteration and modification and such that the present discussion should not be considered limiting.
  • kit is used to denote a bundled assembly of parts and constituents for performing a method.
  • the kit 11 comprises two vials, a first vial 13 containing a polysaccharide for forming a mass in the body of an animal and a second vial 15 containing an enzyme for degrading the polysaccharide for administration to the mass held in the body.
  • the first vial 13 and second vial 15 are bundled or held in a package 17 with means for administering the polysaccharide and means for administering the enzyme, in the form of first syringe 19 and second syringe 21 , and instructions 23.
  • the first vial 13 contains a polysaccharide for forming a mass in the body of an animal or patient.
  • the polysaccharide can be pre-made and in a final form ready for administration or be lyophilized for reconstitution with water.
  • the first syringe 19 is used to withdraw the reconstituted or pre-made polysaccharide for injection into an animal or patient.
  • a human subject may use the mass to conceal wrinkles or to build bulk to areas of the body showing signs of atrophy or for which a fuller appearance is desired.
  • the present kit features a polysaccharide having one or more sugars selected from the group consisting of D-galactose and 3, 6-anhydro-L-galactopyranose. These sugars are constituents of the polysaccharide, agarose, which is used as a dermal filler. Agarose is sold as a dermal filler under the mark ALGINESS ®.
  • the second vial 15 contains an enzyme to effect a modification or speeding the resorption of the mass.
  • the enzyme can be pre-made and in a final form ready for administration or be lyophilized for reconstitution with water.
  • the second syringe 21 is used to withdraw the reconstituted or pre-made polysaccharide for injection into the mass.
  • the subject may desire the mass to have a softer feel.
  • the enzyme is placed in the mass and the mass manipulated to distribute the enzyme where the enzyme may effect a degradation of the polysaccharide. The degradation of the polysaccharide softens the mass.
  • Embodiments of the present invention facilitate the use of polysaccharides, particularly as such polysaccharides are used as fillers and drug delivery vehicles.
  • Embodiments of the present invention allow the polysaccharide to be modified in vivo or in vitro to impart special physical and chemical properties. That is, the enzyme can be distributed into the
  • polysaccharide prior to administration of the polysaccharide or after administration of the polysaccharide to create a desired physical property of texture, feel, resistance to pressure, viscosity and the like.
  • chemical properties of resistance to degradation and speed of degradation can be modified or altered.
  • the modification of physical and chemical features of a polysaccharide used as a filler or drug delivery system allows the health practitioner to modify the filler mass after it has been placed in the body or prior to placement in the body.
  • embodiment of the present invention directed to a method of altering or modifying a mass comprising a polysaccharide held in the body of an animal.
  • the instructions direct the user to reconstitute the polysaccharide held in first vial 13 and the enzyme held in second vial 15 if reconstitution is needed.
  • the instructions 21 direct the user to administer polysaccaride held in the first vial 13.
  • the instructions 21 further direct the user to administer an effective amount of an enzyme for the polysaccharide to the mass.
  • the enzyme can be administered to the mass prior to the mass being placed in the body or after the mass has been placed in the body.
  • Embodiments of the method and kits feature a polysaccharide having one or more sugars selected from the group consisting of D-galactose and 3, 6-anhydro-L-galactopyranose. These sugars are the constituents of algarose. Algarose is used as a dermal filler and as a drug delivery vehicle.
  • Embodiments of the method and kits features an enzyme, agalsidase.
  • the enzyme is selected from the group consisting of agalsidase alpha and agalsidase beta.
  • Algalsidase beta can be administered in doses up to 1 mg/ kg body weight, but is typically used in an amount based on the mass of polysaccharide. Monographs for such enzymes are available from the respective manufacturers and are incorporated herein by reference.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Embodiments of the present invention are directed to kits, compositions and methods for modifying and altering polysaccharide fillers and drug delivery systems with the application of a enzyme.

Description

KITS AND METHODS OF USING ENZYMES TO MODIFY POLYSACCHARIDE FILLERS AND DELIVERY SYSTEMS
Related Applications
This application claims priority to U.S. Provisional Application No. 62/137,558, filed March 24, 2015, the entire contents of which are incorporated herein by reference.
Statement Regarding Federal Funding
Embodiments of the present invention were not conceived or reduced to practice with Federal sponsorship.
Background of the Invention Polysaccharides are used as cosmetic fillers and as a component of injectable drug delivery systems. When polysaccharides are placed in the body as a filler or as a drug delivery system, the polysaccharides may have a long period of time before such are resorbed into the body through metabolism or other means.
Summary of the Invention Embodiments of the present invention facilitate the use of polysaccharides, particularly as such polysaccharides are used as fillers and drug delivery vehicles. Embodiments of the present invention allow the polysaccharide to be modified in vivo or in vitro to impart special physical and chemical properties. For example, without limitation, the physical properties of texture, feel, resistance to pressure, viscosity and the like can be altered or modified, in vivo or in vitro. Similarly, the chemical properties resistance to degradation and speed of degradation can be modified or altered.
The modification of physical and chemical features of a polysaccharide used as a filler or drug delivery system allows the health practitioner to modify the filler mass after it has been placed in the body or prior to placement in the body. As used herein, the term, "mass" refers to the polysaccharide material and the surrounding space it occupies. For example, polysaccharide fillers used for cosmetic purposes typically comprise solutions of 1.0 to 5.0 %. These solutions may also comprise other materials to improve the flow or feel of the filler, such as hyaluronic acid, and anesthetic agents to address the potential discomfort during the administration of the filler. Anesthetic agents are well known in the art and include, without limitation, lidocaine. These fillers are administered to the deep layer of the skin. An example of a filler of this type is described in PCT/IB2014/060322 to Ghimas SPA, the entire content of which is incorporated herein by reference. One embodiment of the present invention is directed to a method of altering or modifying a mass comprising a polysaccharide held in the body of an animal. The method comprises the steps of administering an effective amount of an enzyme for the polysaccharide to the mass. The enzyme can be administered to the mass prior to the mass being placed in the body or after the mass has been placed in the body. One embodiment of the method features a polysaccharide having one or more sugars selected from the group consisting of D-galactose and 3, 6-anhydro-L-galactopyranose. These sugars are the constituents of algarose. Algarose is used as a dermal filler and as a drug delivery vehicle. As used herein, a "drug delivery vehicle" comprises a polysaccharide and one or more drugs. One embodiment of the method features an enzyme, alpha-galactosidase. The enzyme is known in recombinant forms asagalsidase, in alpha and beta forms. For example, without limitation, the enzyme is selected from the group consisting of agalsidase alpha and agalsidase beta. Algalsidase beta is sold under the mark FABRAZYME ® (Genzyme, Cambridge, MA 02142). Algalsidase alpha is sold in Europe under the mark REPLAGAL ® (Shire, Dublin, Ireland).
Wherein the mass is a delivery vehicle for one or more drugs, the enzyme has utility to remove the polysaccharide, control the delivery or release of drug and minimize the mark on the skin from the injection of drug. For example, without limitation, one embodiment of an invention directed to a drug delivery system comprises a polysaccharide and an enzyme for said polysaccharide held in a vessel for reconstitution. Upon reconstitution, the enzyme begin metabolizing the polysaccharide. This metabolizing may continue after injection of the drug delivery system into a patient. As used herein, the term "drug" is used to refer to any compound or compounds used to effect a biological change or treat a medical condition. The drug may be incorporated into the polysaccharide prior to reconstitution or after
reconstitution. Examples of drugs include without limitation, lidocaine, and other anesthetic agents, onabotulinemtoxin A (BOTOX ®, Allergan) and other aesthetic agents. A further embodiment of the present invention is directed to a kit for performing dermal filling procedures or for the administration of drug. The kit comprises a polysaccharide for forming a mass in the body of an animal and an enzyme for degrading the polysaccharide for administration to the mass held in the body to effect a modification or speeding the resorption of said mass.
One embodiment of the present kit features a polysaccharide having one or more sugars selected from the group consisting of D-galactose and 3, 6-anhydro-L-galactopyranose. These sugars are constituents of the polysaccharide, agarose.
One embodiment features the enzyme, agalsidase. The agalsidase is selected from the group consisting of agalsidase alpha and agalsidase beta.
These and other features and advantages will be apparent to those skilled in the art upon viewing the figure which is briefly described below and studying the details description that follows.
Brief Description of the Drawings Figure 1 depicts a kit embodying features of the present invention. Detailed Description of the Invention
Embodiments of the present invention will now be described in detail with respect to a kit for performing dermal filling procedures or for the administration of drug. The present description is directed to embodiments which are considered to be the best mode to practice the present invention at the time of the writing of the present description. Those skilled in the art will recognize that the understanding of the best mode may change in time. Those skilled in the art will also recognize that the features of the present invention described are subject to alteration and modification and such that the present discussion should not be considered limiting. Turning now to Figure 1, a kit, generally designated by the numeral 11, embodying features of the present invention is depicted. The term "kit" is used to denote a bundled assembly of parts and constituents for performing a method. The kit 11 comprises two vials, a first vial 13 containing a polysaccharide for forming a mass in the body of an animal and a second vial 15 containing an enzyme for degrading the polysaccharide for administration to the mass held in the body. The first vial 13 and second vial 15 are bundled or held in a package 17 with means for administering the polysaccharide and means for administering the enzyme, in the form of first syringe 19 and second syringe 21 , and instructions 23.
The first vial 13 contains a polysaccharide for forming a mass in the body of an animal or patient. The polysaccharide can be pre-made and in a final form ready for administration or be lyophilized for reconstitution with water. The first syringe 19 is used to withdraw the reconstituted or pre-made polysaccharide for injection into an animal or patient. For example, a human subject may use the mass to conceal wrinkles or to build bulk to areas of the body showing signs of atrophy or for which a fuller appearance is desired. The present kit features a polysaccharide having one or more sugars selected from the group consisting of D-galactose and 3, 6-anhydro-L-galactopyranose. These sugars are constituents of the polysaccharide, agarose, which is used as a dermal filler. Agarose is sold as a dermal filler under the mark ALGINESS ®.
The second vial 15 contains an enzyme to effect a modification or speeding the resorption of the mass. The enzyme can be pre-made and in a final form ready for administration or be lyophilized for reconstitution with water. The second syringe 21 is used to withdraw the reconstituted or pre-made polysaccharide for injection into the mass. For example, in a human subject using the mass to conceal wrinkles or to build bulk to areas of the body showing signs of atrophy, the subject may desire the mass to have a softer feel. The enzyme is placed in the mass and the mass manipulated to distribute the enzyme where the enzyme may effect a degradation of the polysaccharide. The degradation of the polysaccharide softens the mass.
Embodiments of the present invention facilitate the use of polysaccharides, particularly as such polysaccharides are used as fillers and drug delivery vehicles. Embodiments of the present invention allow the polysaccharide to be modified in vivo or in vitro to impart special physical and chemical properties. That is, the enzyme can be distributed into the
polysaccharide prior to administration of the polysaccharide or after administration of the polysaccharide to create a desired physical property of texture, feel, resistance to pressure, viscosity and the like. Similarly, the chemical properties of resistance to degradation and speed of degradation can be modified or altered.
The modification of physical and chemical features of a polysaccharide used as a filler or drug delivery system allows the health practitioner to modify the filler mass after it has been placed in the body or prior to placement in the body.
The use of the kit and the instructions 21 will now be described with respect to an
embodiment of the present invention directed to a method of altering or modifying a mass comprising a polysaccharide held in the body of an animal. The instructions direct the user to reconstitute the polysaccharide held in first vial 13 and the enzyme held in second vial 15 if reconstitution is needed. The instructions 21 direct the user to administer polysaccaride held in the first vial 13. The instructions 21 further direct the user to administer an effective amount of an enzyme for the polysaccharide to the mass. The enzyme can be administered to the mass prior to the mass being placed in the body or after the mass has been placed in the body.
Embodiments of the method and kits feature a polysaccharide having one or more sugars selected from the group consisting of D-galactose and 3, 6-anhydro-L-galactopyranose. These sugars are the constituents of algarose. Algarose is used as a dermal filler and as a drug delivery vehicle.
Embodiments of the method and kits features an enzyme, agalsidase. For example, without limitation, the enzyme is selected from the group consisting of agalsidase alpha and agalsidase beta. Algalsidase beta can be administered in doses up to 1 mg/ kg body weight, but is typically used in an amount based on the mass of polysaccharide. Monographs for such enzymes are available from the respective manufacturers and are incorporated herein by reference.
Thus, the present invention has been described in detail with the understanding that the present discussion is subject to modification and alteration without departing from the teaching. Therefore, the present invention should not be limited to the precise details but should encompass the subject matter of the claims that follow and their equivalents.

Claims

Claims:
1. A method of altering or modifying a mass comprising a polysaccharide held in the body of an animal comprising the steps of: a. administering an effective amount of an enzyme for the polysaccharide to the mass.
2. The method of claim 1 wherein said polysaccharide has one or more sugars selected from the group consisting of D-galactose and 3, 6-anhydro-L-galactopyranose.
3. The method of claim 1 wherein said enzyme is an agalsidase.
4. The method of claim 3 wherein said agalsidase is selected from the group consisting of agalsidase alpha and agalsidase beta
5. The method of claim 1 wherein said polysaccharide is an agarose.
6. The method of claim 1 wherein said mass is a dermal filler.
7. The method of claim 1 wherein said mass is a deliver vehicle for one or more drugs.
8. A drug delivery system comprising a polysaccharide and an enzyme for said
polysaccharide held in a vessel for reconstitution.
9. The drug delivery system of claim 8 further comprising drug.
10. A kit for performing dermal filling procedures comprising: a. a polysaccharide for forming a mass in the body of an animal; b. an enzyme for degrading said polysaccharide for administration to said mass held in the body to effect a modification or speeding the resorption of said mass.
11. The kit of claim 10 wherein said polysaccharide has one or more sugars selected from the group consisting of D-galactose and 3, 6-anhydro-L-galactopyranose.
12. The kit of claim 10 wherein said enzyme is an agalsidase.
13. The kit of claim 12 wherein said agalsidase is selected from the group consisting of agalsidase alpha and agalsidase beta The kit of claim 10 wherein said polysaccharide is an agarose.
PCT/US2016/023726 2015-03-24 2016-03-23 Kits and methods of using enzymes to modify polysaccharide fillers and delivery systems WO2016154277A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP16769585.7A EP3344064A4 (en) 2015-03-24 2016-03-23 Kits and methods of using enzymes to modify polysaccharide fillers and delivery systems

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562137558P 2015-03-24 2015-03-24
US62/137,558 2015-03-24

Publications (1)

Publication Number Publication Date
WO2016154277A1 true WO2016154277A1 (en) 2016-09-29

Family

ID=56978996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/023726 WO2016154277A1 (en) 2015-03-24 2016-03-23 Kits and methods of using enzymes to modify polysaccharide fillers and delivery systems

Country Status (2)

Country Link
EP (1) EP3344064A4 (en)
WO (1) WO2016154277A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018151827A1 (en) * 2017-02-18 2018-08-23 Advanced Aesthetic Technologies, Inc. Kits and methods of using hyaluronidase to modify polysaccharide fillers and delivery systems

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037776A1 (en) * 2005-08-08 2007-02-15 Tom Richardson Polysaccharides for delivery of active agents
US20090274736A1 (en) * 2006-01-19 2009-11-05 Solazyme Inc. Nutraceutical Compositions From Microalgae And Related Methods of Production And Administration
WO2014162252A1 (en) * 2013-04-04 2014-10-09 Ghimas S.P.A. Filler composition for the treatment of lipoatrophy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004278013B2 (en) * 2003-10-01 2009-01-15 Momenta Pharmaceuticals, Inc. Polysaccharides for pulmonary delivery of active agents
EP1768687A2 (en) * 2004-06-29 2007-04-04 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
WO2010065784A2 (en) * 2008-12-03 2010-06-10 Jakk Group, Inc. Methods, devices, and compositions for dermal filling
US20150216778A1 (en) * 2012-01-18 2015-08-06 Korea University Research And Business Foundation Method for Preparing 3,6-Anhydro-L-Galactose, And Use Thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037776A1 (en) * 2005-08-08 2007-02-15 Tom Richardson Polysaccharides for delivery of active agents
US20090274736A1 (en) * 2006-01-19 2009-11-05 Solazyme Inc. Nutraceutical Compositions From Microalgae And Related Methods of Production And Administration
WO2014162252A1 (en) * 2013-04-04 2014-10-09 Ghimas S.P.A. Filler composition for the treatment of lipoatrophy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3344064A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018151827A1 (en) * 2017-02-18 2018-08-23 Advanced Aesthetic Technologies, Inc. Kits and methods of using hyaluronidase to modify polysaccharide fillers and delivery systems
CN110719770A (en) * 2017-02-18 2020-01-21 高等美容技术公司 Kits and methods for modifying polysaccharide bulking agents and delivery systems using hyaluronidase
EP3582749A4 (en) * 2017-02-18 2020-12-30 Advanced Aesthetic Technologies, Inc. Kits and methods of using hyaluronidase to modify polysaccharide fillers and delivery systems
US11230612B2 (en) 2017-02-18 2022-01-25 Advanced Aesthetic Technologies, Inc. Kits and methods of using hyaluronidase to modify polysaccharide fillers and delivery systems
CN110719770B (en) * 2017-02-18 2024-04-02 高等美容技术公司 Kits and methods for modifying polysaccharide fillers and delivery systems using hyaluronidase

Also Published As

Publication number Publication date
EP3344064A1 (en) 2018-07-11
EP3344064A4 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
HRP20170056T2 (en) Low frequency glatiramer acetate therapy
HRP20211660T1 (en) Methods and compositions for cns delivery of arylsulfatase a
JP2015187125A5 (en)
TW200612987A (en) Combination treatment for non-hematologic malignancies
JP2016514132A5 (en)
BRPI0518460A2 (en) Method for treating an allergic emergency in a patient, drug delivery device containing an epinephrine solution, and kit for treating an allergic emergency '
WO2004082459A3 (en) Methods of administering a material into a patient for dermal enhancement
AU2015275237B2 (en) Compositions and methods for treating joints
HRP20171905A2 (en) Tpp1 formulations and methods for treating cln2 disease
Compston The use of combination therapy in the treatment of postmenopausal osteoporosis
CN104812425A (en) Hand-held pre-filled syringe assembly
RU2015116264A (en) COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE IN PATIENTS WITH DIABETES
JP2018504984A5 (en)
US20220098331A1 (en) Kits and methods of using hyaluronidase to modify polysaccharide fillers and delivery systems
CN109069595A (en) The therapeutical lysosome ferment fused protein of target, its relative allocation object and purposes
WO2016154277A1 (en) Kits and methods of using enzymes to modify polysaccharide fillers and delivery systems
Keni et al. Sculptra (injectable poly-L-lactic acid)
Sahoo et al. Botox In Gummy Smile-A Review.
Su et al. Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles
US20210228468A1 (en) Kits and methods of using ascorbates to modify polysaccharide fillers and delivery systems
Borges et al. Calcitonin: a non-invasive giant cells therapy
Chiam et al. Scedosporium prolificans endogenous endophthalmitis
Schanz et al. Mirror, mirror on the wall: hypercalcemia as a consequence of modern cosmetic treatment with liquid silicone
BRPI0815280A2 (en) medicament comprising an aqueous liquid formulation of g-csf, receptacle for the administration of liquid medicaments, syringe or ampoule, kit for parenteral administration of g-csf
JOP20190019A1 (en) PHARMACEUTICAL COMPOSITION FOR TREATING GROWTH HORMONE DEFICIENCY CONTAINING hGH FUSION PROTEIN

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16769585

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2016769585

Country of ref document: EP